FUTURE SCRIPTS Secure

Please complete ALL information below and fax your request to 1-888-671-5285

Siliq™ Coverage Determination Request Form

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:	Office Contact:	
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)

Medication Name: Select one of the following: ❑ Request is for **GENERIC** ❑ Request is for **BRAND** (unable to take the generic)	Strength:	Dosage Form:
❑ Check if request is for **continuation of therapy**	Directions for Use:	

Clinical Information (required)

Select the Type of Coverage Determination Requested:

❑ **Prior Authorization**- Request is for a drug that requires prior authorization under the plan.

Select the diagnosis below:

❑ Plaque psoriasis

❑ Other diagnosis: ______________________________________ ICD-10 Code(s): _______________________________________

Prescriber's Specialty:

Is the requested medication prescribed by a dermatologist? ❑ **Yes** ❑ **No**

Clinical Information:

Will the patient receive concurrent therapy with biologic DMARDs or other tumor necrosis factor antagonists? ❑ **Yes** ❑ **No**

Has the patient been evaluated for active or latent tuberculosis (TB)? ❑ **Yes** ❑ **No**

For new starts only: Have at least 2 weeks passed since administration of live vaccines prior to the start of therapy? ❑ **Yes** ❑ **No**

Is there documentation the patient has had an inadequate response or inability to tolerate both adalimumab (Humira) AND etanercept (Enbrel)? ❑ **Yes** ❑ **No**

If "no" to the above question, is there documentation demonstrating that a trial of both adalimumab (Humira) and etanercept (Enbrel) may be inappropriate? ❑ **Yes** ❑ **No**

Has the patient been evaluated for depression and suicidal ideations using the PHQ-9? ❑ **Yes** ❑ **No**

Reauthorization:

Will the patient receive concurrent therapy with biologic DMARDs or other tumor necrosis factor antagonists? ❑ **Yes** ❑ **No**

Has the patient been evaluated for active or latent tuberculosis (TB)? ❑ **Yes** ❑ **No**

Is the requested medication prescribed by a dermatologist? ❑ **Yes** ❑ **No**

Has the patient had a positive response to therapy? ❑ **Yes** ❑ **No**

Has the patient been evaluated for depression and suicidal ideations using the PHQ-9? ❑ **Yes** ❑ **No**

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

____

Please note: This request may be denied unless all required information is received.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Siliq_FSPartD_2019Jan-W